UAE-FED-NATIONAL-COUNCIL
9.1.2019 19:16:14 CET | Business Wire | Press release
His Excellency Antonio Tajani, President of the European Parliament, expressed his deep appreciation for the UAE’s global humanitarian and relief efforts, manifested through the work of the Emirates Red Crescent and described them as “really impressive”.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190109005738/en/
His statement came during a brief speech delivered on Tuesday, January 8, 2019, during the opening of the three-day ‘Humanitarian Aid for Stability’ exhibition at the European Parliament in Brussels, Belgium. The event was organized by the Emirates Red Crescent in coordination with the Federal National Council (FNC), the parliamentary body of the UAE.
The opening of the exhibition drew the participation of Her Excellency Dr Amal Al Qubaisi, Speaker of FNC, His Excellency Fahad Abdelrahman Bin Sultan, Deputy Secretary General for International Aid at the Emirates Red Crescent, members of the European Parliament, and several ambassadors.
His Excellency Antonio Tajani called for joint action between the UAE and Europe to deal with illegal immigration, expand cooperation in this regard to the Middle East and Africa, and strengthen collaborative efforts to combat terrorism and enhance security. He added that ensuring stability and promoting development efforts in the world are common goals for the UAE and the EU.
His Excellency Antonio Tajani stressed that the refugee crisis is a global challenge, and therefore humanitarian aid must be a collective task that engages nations and peoples.
Furthermore, he thanked Antonio López-Istúriz White, Secretary General of the European People’s Party and member of the European Parliament, for his initiative in holding the exhibition that presented a novel opportunity to showcase the endeavors of valued partners of the EU to help alleviate the devastating effects of war. He added that war and natural disasters are the reasons for thousands of migrants trying to seek refuge in Europe.
His Excellency Antonio Tajani said: “The exhibition carries the positive message of hope. Yes, hope, because helping each other, providing a roof for people in need is providing hope, and hope is the fuel for a better tomorrow.”
In closing, he invited guests to view the exhibition that included a model of the Mrajeeb Al Fhood camp for Syrian refugees in Jordan and an interactive world map of areas in which the Emirates Red Crescent operates. He also highlighted the EU’s humanitarian commitment to helping refugees that places it at the forefront of humanitarian aid providers globally, and called for reinstating stability and security in the refugees’ home countries to overcome this global challenge.
Speaking on the sidelines of the launch of the exhibition, His Excellency Fahad Abdelrahman Bin Sultan said: “The humanitarian and development aid offered by the UAE to the world amounted to US$32.01 billion from 2013 to 2017 and benefited millions of people across the globe, including 10 million Yemenis.”
He added: “This exhibition is the first of its kind outside the UAE and was organized at the request of the European Parliament to explore the UAE’s international humanitarian, relief, and development role that is based on the country’s noble values and enhances the global humanitarian ecosystem.”
His Excellency Fahad Abdelrahman Bin Sultan stressed that the UAE humanitarian and development aid focuses on meeting the needs of refugees and displaced civilians in volatile areas, such as Syria, Yemen, Somalia, Palestine, Afghanistan, and Iraq. He pointed out that the UAE has gained international respect and trust, and placed first globally for the fifth consecutive year for its contribution of humanitarian and development aid relative to national GDP.
He noted that more than 100 countries have benefited from aid provided by the UAE, adding that the Emirates Red Crescent has 14 offices in countries such as Yemen, Somalia, Kazakhstan, Indonesia, Pakistan, Afghanistan, Bosnia, and Albania.
His Excellency Fahad Abdelrahman Bin Sultan outlined the distribution of the UAE humanitarian aid as follows: US$4.92 billion to Yemen from April 2015 to December 2018, around US$174.6 million to Libya from 2013 to 2017, around US$963.5 million to the Syrian people from 2012 to November 2018, around US$641.5 million to the people of Erbil (Iraq) from 2013 to 2017, around US$233.3 million to Somalia from 2013 to 2017, US$489 million to Palestinians from 2013 to 2018, and US$333.3 million to Afghanistan from 2013 to 2017.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20190109005738/en/
Contact:
Federal National Council, United Arab Emirates : Mohammed Al-Sawafi, +971506183874 m.alsawwafi@almajles.gov.ae Twitter: @FNC_UAE
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom